药格局 YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
2022/05/24 – 2022/05/30
- New acceptances this week
- 284
- Drugs with new generic filings (by drug name, de-duplicated)
- 40
- Accepted this week, now under review
- 1
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Drug and company names link to detail pages; sign in to view them.
New acceptances this week
By application type and drug type
284filings, 57 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 129 |
| Generic | 57 |
| New drug | 47 |
| Import | 27 |
| Unspecified | 13 |
| Import re-registration | 11 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 201 |
| 治疗用生物制品 | 45 |
| TCM | 30 |
| Biologic | 7 |
| 预防用生物制品 | 1 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
40 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 注射用哌拉西林钠 | 5 | 2 | 16 |
| 2 | 哌柏西利胶囊 | 3 | 1 | 0 |
| 3 | 阿普米司特片 | 3 | 1 | 3 |
| 4 | 依帕司他片 | 2 | 2 | 1 |
| 5 | 厄贝沙坦氨氯地平片 | 2 | 1 | 1 |
| 6 | 布地奈德鼻喷雾剂 | 2 | 1 | 3 |
| 7 | 拉莫三嗪分散片 | 2 | 1 | 2 |
| 8 | 盐酸多巴胺注射液 | 2 | 1 | 3 |
| 9 | 硫酸特布他林注射液 | 2 | 1 | 2 |
| 10 | 米拉贝隆缓释片 | 2 | 1 | 1 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
161 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | 亳州亚英医药科技有限公司 | 6 | 6 | 0 |
| 2 | 江西远东药业股份有限公司 | 6 | 6 | 0 |
| 3 | 齐鲁制药有限公司 | 6 | 3 | 0 |
| 4 | 江右制药（常德）有限公司 | 5 | 4 | 0 |
| 5 | Novartis Pharma AG | 5 | 3 | 0 |
| 6 | Novartis Pharma Schweiz AG | 5 | 2 | 0 |
| 7 | 海南赞邦制药有限公司 | 5 | 2 | 0 |
| 8 | ASPEN PHARMA TRADING LIMITED | 5 | 1 | 0 |
| 9 | 吉林省都邦药业股份有限公司 | 5 | 1 | 0 |
| 10 | 仁合益康集团有限公司 | 4 | 3 | 1 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
87 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2022/05/28Import · Class 3.1 | Netakimab注射液JXSL2200066 | Joint Stock Company “BIOCAD”，(JSC “BIOCAD”); SPH-Biocad Biopharmaceuticals (SH) Co. Ltd. |
| 2022/05/28Import · Class 2.2 | 二氟泼尼酯滴眼液JXHL2200123 | SUN PHARMACEUTICAL INDUSTRIES LTD. |
| 2022/05/28Import · Class 1 | EnpatoranJXHL2200122 | Merck Healthcare KGaA; Merck Serono (Beijing) Pharmaceutical R&D Co. Ltd. |
| 2022/05/28Import · Class 1 | EnpatoranJXHL2200121 | Merck Healthcare KGaA; Merck Serono (Beijing) Pharmaceutical R&D Co. Ltd. |
| 2022/05/28Generic · Class 3 | 依帕司他片CYHS2200799 | 浙江恒研医药科技有限公司; 浙江赛默制药有限公司 |
| 2022/05/28New drug · Class 1 | 伊基仑赛注射液CXSL2200234 | 南京驯鹿生物医药有限公司 |
| 2022/05/28New drug · Class 1 | 伊基仑赛注射液CXSL2200233 | 南京驯鹿生物医药有限公司 |
| 2022/05/28New drug · Class 1 | EOC202注射液CXSL2200232 | 泰州亿腾景昂药业股份有限公司 |
| 2022/05/28New drug · Class 2.2 | 盐酸多奈哌齐口溶膜CXHL2200341 | 浙江和泽医药科技股份有限公司 |
| 2022/05/28New drug · Class 2.2 | 恩扎卢胺片CXHL2200339 | 四川科伦药物研究院有限公司 |
| 2022/05/27Import · Class 3.1 | 司美格鲁肽片JXSS2200018 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd. |
| 2022/05/27Import · Class 3.1 | 司美格鲁肽片JXSS2200017 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd. |
| 2022/05/27Import · Class 3.1 | 司美格鲁肽片JXSS2200016 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd. |
| 2022/05/27Import · Class 1 | VAY736注射液JXSL2200067 | Novartis Pharma AG; China Novartis Institutes for BioMedical Research Co. Ltd. |
| 2022/05/27Generic · Class 3 | 盐酸多巴胺注射液CYHS2200790 | 呋欧医药科技（湖州）有限公司; 安徽长江药业有限公司 |
| 2022/05/27Generic · Class 3 | 盐酸多巴胺注射液CYHS2200789 | 呋欧医药科技（湖州）有限公司; 安徽长江药业有限公司 |
| 2022/05/27Generic · Class 3 | 氨溴特罗口服溶液CYHS2200783 | 成都利尔药业有限公司 |
| 2022/05/27Generic · Class 3 | 依帕司他片CYHS2200777 | 石家庄四药有限公司 |
| 2022/05/27Generic · Class 3 | 阿立哌唑口服溶液CYHS2200776 | 西洲医药科技（浙江）有限公司; 浙江赛默制药有限公司 |
| 2022/05/27Generic · Class 3 | 厄贝沙坦氨氯地平片CYHL2200045 | 湖南慧泽生物医药科技有限公司 |
| 2022/05/27Generic · Class 3 | 厄贝沙坦氨氯地平片CYHL2200044 | 湖南慧泽生物医药科技有限公司 |
| 2022/05/27New drug · Class 3.4 | 人凝血因子ⅧCXSS2200054 | 深圳市卫光生物制品股份有限公司 |
| 2022/05/27New drug · Class 1 | 泽美洛韦玛佐瑞韦单抗注射液CXSS2200053 | 兴盟生物医药（苏州）有限公司 |
| 2022/05/27New drug · Class 1 | 泽美洛韦玛佐瑞韦单抗注射液CXSS2200052 | 兴盟生物医药（苏州）有限公司 |
| 2022/05/27New drug · Class 3.2 | 外用重组人凝血酶CXSS2200051 | 苏州泽璟生物制药股份有限公司 |
| 2022/05/27New drug · Class 1 | 赫基仑赛注射液CXSL2200231 | 合源生物科技（天津）有限公司 |
| 2022/05/27New drug · Class 3.2 | 静注人免疫球蛋白CXSL2200230 | 深圳市卫光生物制品股份有限公司 |
| 2022/05/27New drug · Class 3.2 | 静注人免疫球蛋白CXSL2200229 | 深圳市卫光生物制品股份有限公司 |
| 2022/05/27New drug · Class 1 | B1962注射液CXSL2200226 | 天士力生物医药股份有限公司 |
| 2022/05/27New drug · Class 1 | HR20014注射液CXSL2200225 | 江苏恒瑞医药股份有限公司 |
57 more not listed (at most 30 rows).
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.